文献速递骨软组织肉瘤与黑色素瘤

辅助抗PD-1治疗用于已切除的III/IV期肢端或黏膜黑色素瘤患者的结局

Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy.
PubMed 文献 · Eur J Cancer · 2024-01-22

这项国际回顾性队列研究纳入194例已切除III/IV1期肢端或黏膜黑色素瘤患者,接受辅助抗PD-1治疗,并与澳大利亚黑色素瘤研究所数据库匹配患者比较。肢端组无复发生存(HR 0.69)、无远处转移生存(HR 0.58)和总生存(HR 0.59)均优于历史队列;黏膜组无统计学差异。

要点

  • 肢端黑色素瘤辅助抗PD-1较历史队列延长无复发生存(HR 0.69)、无远处转移生存(HR 0.58)和总生存(HR 0.59)。
  • 黏膜黑色素瘤辅助抗PD-1的无复发生存、无远处转移生存和总生存均与历史队列无统计学差异。
  • 两组早期停药主因均为疾病复发,肢端组51例(37%)、黏膜组30例(55%)。

核心结论

  • 辅助抗PD-1治疗后肢端和黏膜黑色素瘤均有高复发风险。
  • 数据提示辅助抗PD-1对已切除肢端黑色素瘤有获益,但对已切除黏膜黑色素瘤无获益。
  • 需要额外研究探讨辅助抗PD-1对黏膜黑色素瘤的疗效。

研究设计与样本

  • 国际回顾性队列研究,数据截至2021年11月,来自10个国家20个中心。
  • 纳入194例已切除III期或IV1期肢端或黏膜黑色素瘤并接受辅助抗PD-1治疗的患者。
  • 与澳大利亚黑色素瘤研究所(MIA)数据库匹配患者进行倾向性评分匹配分析。

主要发现

  • 139例肢端黑色素瘤中45例(32%)完成辅助治疗,55例黏膜黑色素瘤中9例(16%)完成辅助治疗。
  • 肢端组早期停药主因为疾病复发51例(37%),黏膜组为30例(55%)。

临床怎么用

  • 作者认为数据提示辅助抗PD-1对已切除肢端黑色素瘤有获益,对已切除黏膜黑色素瘤无获益。
  • 作者提出需要额外研究探讨辅助抗PD-1对黏膜黑色素瘤的疗效。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Acral (AM) and mucosal melanomas (MM) are rare subtypes with a poor prognosis. In those with advanced disease, anti-PD-1 (PD1) therapy has reduced activity compared to that seen in non-acral cutaneous melanoma. OBJECTIVE: To determine the efficacy of adjuvant PD1 in resected AM or MM. DESIGN: An international, retrospective cohort study SETTING: Data up to November 2021 collected from 20 centres across 10 countries. PARTICIPANTS: One hundred and ninety four patients with resected stage III or IV1 AM or MM who received adjuvant PD1 were included and compared to matched patients from the Melanoma Institute Australia (MIA) database using a propensity score matching analysis. MAIN OUTCOMES AND MEASURES: Recurrence-free survival (RFS), distant metastasis-free survival (DMFS) and overall survival (OS) were investigated. RESULTS: Forty five of 139 (32%) AM and 9 of 55 (16%) MM patients completed adjuvant therapy. The main reason for early treatment cessation in both groups was disease recurrence: 51 (37%) and 30 (55%) in the AM and MM groups, respectively. In the AM group adjuvant PD1 was associated with a longer RFS [HR-0.69 (0.52-0.92, p = 0.0127)], DMFS [HR0.58 (0.38-0.89, p = 0.0134)] and OS [HR of 0.59 (0.38-0.92, p-value 0.0196)] when compared to the historical cohort. In the MM group there was no statistical difference in RFS [HR1.36 (0.69-2.68,p-value 0.3799], DMFS or OS. CONCLUSION AND RELEVANCE: After adjuvant PD1, both AM and MM have a high risk of recurrence. Our data suggests a benefit to using adjuvant PD1 therapy in resected AM but not in resected MM. Additional studies to investigate the efficacy of adjuvant PD1 for MM are needed.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Jacques SK, McKeown J, Grover P, et al. Outcomes of patients with resected stage III/IV acral or mucosal melanoma, treated with adjuvant anti-PD-1 based therapy. Eur J Cancer. 2024. PMID: 38278007. doi:10.1016/j.ejca.2024.113563

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。